Home > Resources > Company Profiles > Johnson & Johnson

Johnson & Johnson (JNJ)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

William C. Weldon , CEO/Chairman of the Board/Director

www.jnj.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A holding company, which is engaged in research and development, manufacture and sale of products in the health care field. It focuses on products related to human health and well-being.

News Feeds

J&J gets exclusivity period on Topamax extended AP
Jul 24 2008
J&J found not liable in Motrin lawsuit Reuters
Jul 18 2008
Earnings Preview: Schering-Plough AP
Jul 18 2008
Sector Snap: Weak dollar aids drugmakers' earnings AP
Jul 17 2008
Johnson & Johnson posts 8 pct profit jump in Q2 AP
Jul 15 2008
Earnings roundup: Johnson & Johnson, US Bancorp AP
Jul 15 2008
Out of the Gate: Johnson & Johnson shares rise AP
Jul 15 2008
Earnings Preview: Johnson & Johnson AP
Jul 14 2008
Amgen to pay J&J $200 million to settle antitrust suit Reuters
Jul 11 2008
Amgen paying J&J $200 million in settlement AP
Jul 11 2008

Portfolio Blogs

Citi Trading Below Book
Mar 05 2008
The Last AAAngels Standing
Aug 16 2007
The Travails of Johnson & Johnson
Aug 14 2007

Eating Up the AAA
Aug 14 2007

Press Releases

LecTec Corporation Files Patent Infringement Lawsuit Jul-25-2008, 01:52PM EDT
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months Jul-24-2008, 04:15PM EDT
Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Bipolar Disorder Jul-24-2008, 08:30AM EDT
Who Really Profits From Smoking Bans? Jul-23-2008, 12:07PM EDT
Research and Markets: Medical Equipment Company Share Analysis Report for Johnson & Johnson Vision Care, Inc. Jul-23-2008, 09:00AM EDT

News From Around the Web

News

FDA Grants Pediatric Exclusivity For TOPAMAX® (Medical News Today)

Jul 26 2008
FDA Grants Pediatric Exclusivity for Topamax, Extending the Marketing Exclusivity by Six Months (PharmaLive)

Jul 25 2008
ADVERTISING: Companies line up under Olympics logo (Courier-Post Online)

Jul 25 2008
Medical students learn art of suturing (The Hindu)

Jul 25 2008
J&J gets exclusivity period on Topamax extended (Boston Globe)

Jul 24 2008
If Your Home is Damaged or Destroyed ... (MSN Money)

Jul 24 2008
Johnson & Johnson Breaks Resistance, Hits Highest Level In Over A Year (RTTNews)

Jul 24 2008
Who Really Profits From Smoking Bans? (Examiner)

Jul 23 2008

Blogs

For blue chip buyers: 'This too shall pass' (Blogging Stocks)

Jul 25 2008
The State of Statins & Stents (CNBC: Pharmas Market with Mike Huckman)

Jul 25 2008
Is Pfizer's Viagra "Sagging" With The Economy? (CNBC: Pharmas Market with Mike Huckman)

Jul 23 2008

Employees

Number of Employees: 119,200

Revenue per Employee: $499,959

Top Executives

Stephen J. Cosgrove, Controller/Chief Accounting Officer

Kaye I. Foster-Cheek, Divisional Vice President

Russell C. Deyo, Vice President/General Counsel

Dominic J. Caruso, Divisional Vice President/CFO

Nicholas J. Valeriani, Vice President, Divisional

Board of Directors

Dr. Susan L. Lindquist, Ph.D., Director

Arnold G. Langbo, Director

Dr.Michael M. E. Johns, M.D., Director

Steven S. Reinemund, Director

Colleen A. Goggins, Chairman of the Board, Divisional

Leo F. Mullin, Director

Dr. David Satcher, M.D., Ph.D., Director

Donald M. Casey, Jr., Chairman of the Board, Divisional

James G. Cullen, Director

Dr.Mary Sue Coleman, Director

Sherilyn S. McCoy, Chairman of the Board, Divisional

Charles Prince, Director

Christine A. Poon, Director/Vice Chairman/Chairman of the Board, Divisional

William D. Perez, Director

Financials

Quarterly

Annual

Income Statement	07/2008	05/2008	01/2008	11/2007
Sales	4.75 Bil.	3.95 Bil.	4.73 Bil.	3.68 Bil.
Gross Operating Profit	11.7 Bil.	12.25 Bil.	11.22 Bil.	11.29 Bil.
Operating Income before D & A (EBITDA)	4.3 Bil.	5.41 Bil.	3.17 Bil.	4.56 Bil.
Total Income Before Interest Expenses (EBIT)	4.12 Bil.	4.84 Bil.	2.33 Bil.	3.35 Bil.
Total Net Income	3.33 Bil.	3.6 Bil.	2.37 Bil.	2.55 Bil.
Basic EPS, Total	1.17	1.27	0.82	0.88
Diluted EPS, Total	1.17	1.26	0.82	0.88

BALANCE STATEMENT	07/2008	05/2008	01/2008	11/2007
Cash and Equivalents	NA	10.54 Bil.	NA	6.64 Bil.
Total Assets	NA	33.82 Bil.	NA	28.94 Bil.
Total Liabilities	NA	22.07 Bil.	NA	19.33 Bil.
Total Capitalization	NA	52.79 Bil.	NA	48.21 Bil.

Cash Flow	07/2008	05/2008	01/2008	11/2007
Net Cash From Continuing Operations	NA	3.24 Bil.	NA	10.92 Bil.
Net Cash From Investing Activities	NA	452 Mil.	NA	-4.74 Bil.
Net Cash From Financing Activities	NA	-1.11 Bil.	NA	-3.85 Bil.
Net Change in Cash & Cash Equivalents	NA	2.77 Bil.	NA	2.56 Bil.

Income Statement	2008	2007	2006	2005
Sales	17.75 Bil.	12.88 Bil.	11.86 Bil.	11.3 Bil.
Gross Operating Profit	43.34 Bil.	40.44 Bil.	38.65 Bil.	36.05 Bil.
Operating Income before D & A (EBITDA)	15.21 Bil.	15.89 Bil.	15.46 Bil.	14.99 Bil.
Total Income Before Interest Expenses (EBIT)	13.28 Bil.	14.65 Bil.	13.71 Bil.	13.02 Bil.
Total Net Income	10.58 Bil.	11.05 Bil.	10.41 Bil.	8.51 Bil.
Basic EPS, Total	3.63	3.76	3.5	2.87
Diluted EPS, Total	3.63	3.73	3.46	2.84

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	4.08 Bil.	16.06 Bil.	9.2 Bil.
Total Assets	NA	22.98 Bil.	31.39 Bil.	27.32 Bil.
Total Liabilities	NA	19.16 Bil.	12.64 Bil.	13.93 Bil.
Total Capitalization	NA	41.33 Bil.	39.89 Bil.	34.38 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	14.25 Bil.	11.88 Bil.	11.13 Bil.
Net Cash From Investing Activities	NA	-20.29 Bil.	-279 Mil.	-2.35 Bil.
Net Cash From Financing Activities	NA	-6.11 Bil.	-4.52 Bil.	-5.15 Bil.
Net Change in Cash & Cash Equivalents	NA	-11.97 Bil.	6.85 Bil.	3.83 Bil.

Johnson & Johnson (JNJ)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request